Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Serina Therapeutics (SER) over the last 6 years, with Q3 2025 value amounting to $13000.0.

  • Serina Therapeutics' Capital Expenditures rose 33333.33% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $64000.0, marking a year-over-year decrease of 2643.68%. This contributed to the annual value of $22000.0 for FY2024, which is 9563.49% down from last year.
  • As of Q3 2025, Serina Therapeutics' Capital Expenditures stood at $13000.0, which was up 33333.33% from $46000.0 recorded in Q2 2025.
  • Over the past 5 years, Serina Therapeutics' Capital Expenditures peaked at $119000.0 during Q3 2023, and registered a low of $3000.0 during Q3 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $14000.0 (2024), whereas its average is $38571.4.
  • Per our database at Business Quant, Serina Therapeutics' Capital Expenditures tumbled by 9747.9% in 2024 and then soared by 33333.33% in 2025.
  • Over the past 3 years, Serina Therapeutics' Capital Expenditures (Quarter) stood at $70000.0 in 2023, then crashed by 92.86% to $5000.0 in 2024, then skyrocketed by 160.0% to $13000.0 in 2025.
  • Its Capital Expenditures stands at $13000.0 for Q3 2025, versus $46000.0 for Q2 2025 and $5000.0 for Q4 2024.